Abstract: The invention provides assays and methods for detecting and monitoring systemic inflammation. Particularly, the invention in embodiments thereof relates to the use of urinary biomarkers for non-invasive determination of the level of inflammation.

Abstract: A method for generating an indication for Parkinson's Disease in a subject is disclosed. The method comprises measuring, whilst the subject is awake, air flow in the nose of the subject during a plurality of nasal respirations using a sensor; receiving, by a device, data associated with said air flow measurements received from said sensor; and evaluating at least one respiration parameter received from said data, generating an indication for Parkinson's Disease of the subject based on the at least one respiration parameter.

Abstract: A method for reinforcing a cellularized retinal construct fabricated from (i) endothelial cells; (ii) retinal pigment epithelial cells and/or photoreceptors; and (iii) an extracellular matrix (ECM) hydrogel is disclosed. The method comprises contacting the construct with a biocompatible small-molecule reinforcing agent that is capable of chemically interacting with the ECM hydrogel under conditions that maintain viability of the cells, to thereby increase a compressive modulus of the ECM hydrogel by at least 10%.

Abstract: The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.

Abstract: Compositions and methods for treating cancer and inhibiting tumor development are provided. More specifically, provided in embodiments of the invention are novel klotho-derived recombinant polypeptides exhibiting tumor suppressor activity, characterized by a distinct structure and improved properties compared to hitherto known klotho polypeptides.

Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

Abstract: Embodiments described herein use deep learning to automate measurement of key morphokinetic embryo features associated with viability and quality, in particular those relevant for clinical in-vitro fertilization (IVF). Systems and methods may, for example, acquire one or more digital images of one or more embryos; select one or more embryos in each digital image; and for each selected embryo, (i) computationally characterize the zona pellucida, detect the degree of fragmentation in the embryo, and for each embryo with a low fragmentation score, computationally classify the embryo's developmental stage based on whether cells constituting the embryo exceed a threshold number (e.g., nine). For an embryo consisting of a single cell, pronuclei may be detected and counted. Based on these measurements, a viability score may be assigned to the embryo.

Abstract: The present invention relates to fusion proteins comprising a proteinaceous therapeutic agent. Particularly, the present invention relates to fusion proteins comprising a two-domain carrier protein linked via a peptide linker to a proteinaceous therapeutic agent, wherein the two-domain carrier protein comprises a transferrin receptor binding peptide linked to granulocyte colony stimulating factor (G-CSF), pharmaceutical compositions comprising same and uses thereof for treating CNS diseases.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: The present invention is directed to a method for inducing an immune response in a subject, including a step of activating neurons in the mesolimbic network of the subject by applying a neurofeedback.

Abstract: Provided herein are methods for EEG monitoring of a patient, which includes: positioning an array comprising a plurality of EEG electrodes on the patient's head; recording, during a first time period, a first data set of EEG signals from a first set of spatial scalp locations; manipulating the array to record, during a second time period, a second data set of EEG signals from a second set of spatial locations including at least some spatial scalp locations that are different from the first set of spatial scalp locations; integrating the first and second data sets, thereby generating a combined data set with a higher spatial density; and processing the combined data set to determine EEG events.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

Abstract: Compounds represented by Formula A as defined in the specification for use in treating skin diseases such as, for example, psoriasis, or atopic dermatitis, in a subject in need thereof are disclosed. Compositions containing these compounds, formulated for topical application, are also disclosed.

Abstract: A method of prognosing a subject diagnosed with multiple myeloma (MM) is provided. Also provided a method of treating a subject diagnosed with MM selected expressing intracellular PPIA and/or RRM2 above a predetermined threshold, the method comprising administering to the subject a therapeutically effective amount of at least one agent which specifically down-regulates activity or expression of PPIA and/or RRM2, thereby treating the subject.

Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.

Abstract: A neurofeedback method, including: recording electrical signals from at least one brain region of a subject, wherein changes in the recorded electrical signals over time indicate changes in an activity level of the at least one brain region; providing an audio signal having a perceived quality based on the recorded electrical signals and according to an activity level of the at least one brain region; delivering the audio signal to the subject during said recording.

Abstract: A method of treating atopic dermatitis (AD) in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of at least two species of bacteria.

Abstract: An anti-CD24 antibody is provided. Accordingly, there is provided an antibody comprising an antigen recognition domain which specifically binds CD24 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 2, 3 and 4 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 6, 7 and 8 arranged in a sequential order from N to C on a heavy chain of said antibody. Also provided are polynucleotides encoding the antibody, host cells expressing the antibody the uses thereof.